HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors

Magda Zammataro  
*University of Catania*

Maria Angela Sortino  
*University of Catania*

Carmela Parenti  
*University of Catania*

Robert W. Gereau IV  
*Washington University School of Medicine in St. Louis*

Santina Chiechio  
*University of Catania*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

**Recommended Citation**

Zammataro, Magda; Sortino, Maria Angela; Parenti, Carmela; Gereau, Robert W. IV; and Chiechio, Santina, "HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors." Molecular Pain. 10., 68. (2014).  
[https://digitalcommons.wustl.edu/open_access_pubs/3527](https://digitalcommons.wustl.edu/open_access_pubs/3527)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors

Magda Zammataro1,2, Maria Angela Sortino2, Carmela Parenti1, Robert W Gereau IV3 and Santina Chiechio1*

Abstract

Background: Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are key players in epigenetic regulation of gene expression. Analgesic activity by HDAC inhibitors has been reported in different pain models including inflammatory and neuropathic pain. These drugs interfere with gene expression through different mechanisms including chromatin remodeling and/or activation of transcription factors. Among other targets, HDAC inhibitors regulate metabotropic glutamate receptors type 2 (mGlu2) expression in central and peripheral nervous system. However whether inhibition of HAT activity also regulates mGlu2 expression has not been reported.

Findings: Here we report that curcumin (CUR), a naturally occurring compound endowed with p300/CREB-binding protein HAT inhibitory activity, is able to induce a drastic down-regulation of the mGlu2 receptor in the mouse spinal cord after systemic administration together with a marked hypoacetylation of histones H3 and H4 in dorsal root ganglia (DRG). Furthermore, the analgesic activity of the mGlu2/3 agonist, LY379268 is lost after a 3-day treatment with CUR. Conversely the analgesic activity of LY379268 is potentiated in mice pretreated for 5 consecutive days with the HDAC inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), known to induce mGlu2-upregulation.

Conclusions: Our results demonstrate that systemically injected CUR is able to inhibit H3 and H4 acetylation in the DRG and to down-regulate mGlu2 receptors in the spinal cord. We also demonstrate that long term modification of the mGlu2 expression affects the analgesic properties of the orthosteric mGlu2/3 agonist, LY379268. These data open up the possibility that epigenetic modulators might be given in combination with “traditional” drugs in a context of a multi target approach for a better analgesic efficacy.

Keywords: Inflammatory pain, mGlu2, Curcumin, Epigenetic modulation, HDAC, HAT

Findings

Background

Histone deacetylases (HDACs) and histone acetyltransferases (HATs) are two families of enzymes that regulate the acetylation status of lysine residues of histone tails, thus behaving as a chromatin modulators. The hyper- or hypo-acetylation state of chromatin impacts on the accessibility of specific DNA sequences to transcription factors and other modulators of gene expression. Thus, HDAC or HAT inhibitors act as epigenetic modulators able to induce long-term changes in gene expression [1,2]. Beside histones, HDACs and HATs also target non-histone proteins and transcription factors therefore modulating the expression of a number of receptors, ion channels and other downstream targets [3]. HDAC inhibitors and acetylating agents have been shown to induce analgesia in different models of inflammatory pain [1,4-9] and to alleviate nerve injury-induced hypersensitivity [8-14]. Several epigenetic mechanisms have been proposed to explain the analgesic activity of HDAC inhibitors. We first reported that an increased expression of the metabotropic glutamate receptor type 2 (mGlu2) in the spinal cord and dorsal root ganglia (DRG) is responsible for the analgesic effect of two different HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA) and N-(2-aminophenyl)-4-[N-(pyridine-3-ylmethoxy-carbonyl)aminomethyl] benzamide

* Correspondence: chiechio@unict.it
1Department of Drug Sciences, Section of Pharmacology and Toxicology, University of Catania, 95125 Catania, Italy
Full list of author information is available at the end of the article

© 2014 Zammataro et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
(MS275) in the second phase of the formalin test [5]. The mechanism underlying the mGlu2 overexpression induced by HDAC inhibitors has been related to the activation of the NF-κB pathway by an increased acetylation of the p65 subunit at lysine 310 (K310) [5,6].

With this study we sought to evaluate whether inhibition of HAT activity might affect mGlu2 expression and thus have an impact on mGlu2-mediated analgesia. To test this hypothesis we used a naturally occurring compound endowed with p300/CREB-binding protein (CBP) histone HAT inhibitory activity, curcumin (CUR), extracted from rhizomes of turmeric Curcuma longa [15-17]. We also evaluated the analgesic effect of the mGlu2/3 agonist, LY379268, in mice in which the expression of the mGlu2 receptor was epigenetically modulated.

Results and discussion
We examined the effect of repeated injection with the naturally occurring p300/CBP HAT inhibitor, CUR, on the mGlu2 expression level in the spinal cord. Chronic administration of CUR at doses ranging from 50 to 300 mg/kg have been shown to be well tolerated in behavioral studies [18]. Intraperitoneally injected CUR (100 mg/kg) is able to decrease histone acetylation in the CNS only after inclusion in nanostructured lipid carriers [17]. In this study we demonstrated that CUR (100 mg/kg, ip) was able to significantly reduce the mGlu2 receptor expression in the mouse spinal cord after 24 hours from the injection with a lowest level reached after 3 consecutive days of administration (Figure 1). However no further reduction in mGlu2 receptor expression was observed after a more prolonged treatment such as a 5-day treatment (data not shown). Systemically injected, CUR was also able to induce a significant H3 and H4 hypoacetylation in the DRG (Figure 2A, 2B). Since mGlu2 receptors play an important role in pain behavior and in the analgesic effects of mGlu2/3 agonists [19] we next evaluated whether a 3-day CUR administration has an impact on pain behavior in the mouse formalin test and/or affects the analgesic activity of the mGlu2/3 agonist, LY379268. mGlu2/3 agonists are known to induce analgesia in different pain models including the formalin test [10,19-29]. Consistent with data from literature, a single administration of LY379268

![Figure 1 Expression of mGlu2 receptors in the mouse spinal cord after curcumin treatment.](image)

A single or repeated injections of CUR (100 mg/kg, ip) decreased the expression of mGlu2 receptors in the lumbar segment of the spinal cord. Data are the means ± S.E.M. of 4 animals. *p < 0.05 (Student’s t test) versus values obtained in animals treated with vehicle.
(3 mg/kg, ip) 30 minutes before formalin injection, was able to induce analgesia in the mouse formalin test (Figure 3A-D). Also, to test the effect of a 3-day treatment with CUR on the analgesic activity of LY379268 we pretreated mice with CUR (100 mg/kg, ip) for three consecutive days with the last injection 24 hours before the formalin test and then mice received either saline or LY379268 30 minute before the formalin injection. Although CUR was able to induce mGlu2 downregulation, mice receiving a 3-day pretreatment with CUR exhibited a slight but not significant increase of pain behavior in the second phase of the formalin test compared to saline-injected mice (Figure 3A,B). However, under these conditions, the analgesic effect of LY379268, was lost (Figure 3A,B). We then moved to test whether repeated injection with the HDAC inhibitor, SAHA, would affect the analgesic activity of the mGlu2/3 agonist, LY379268. To address this question we pretreated mice with SAHA (5 mg/Kg, sc) for 5 consecutive days. As previously shown [5], while a single injection of SAHA is not analgesic and does not affect mGlu2 receptor expression in the mouse spinal cord, a 5-day pretreatment is sufficient to upregulate mGlu2 receptors and to reduce the second phase of the mouse formalin test [5]. Here we show that, opposed to Curcumin, when mice were pretreated with SAHA (5 mg/kg, sc) for 5 consecutive days with the last injection 24 hours before the formalin injection the analgesic effect of LY379268 (3 mg/kg, ip), acutely injected 30 minutes before formalin injection, was potentiated in the second phase of the formalin test (Figure 3C,D).

Our data show that epigenetic modulation of mGlu2 receptors affects the analgesic activity of orthosteric mGlu2/3 ligands. It has been shown that mGlu2 expression is regulated by epigenetic mechanism in peripheral and central nervous system regions including DRG, spinal cord [5,9], and prefrontal cortex [30]. Particularly, pharmacological treatments leading to protein hyperacetylation, such as HDAC inhibitors or L-acetylcarnitine, have been shown to increase the expression of mGlu2 receptor both in in vivo and in vitro experiments [5,6,9,10,30-32] and to induce analgesia in the second phase of the mouse formalin test [5,6]. However, no report indicates whether a decreased protein acetylation level might influence the expression of mGlu2 receptor and thus have an impact on mGlu2/3 agonist-induced analgesia. As a p300/CBP HAT inhibitor, CUR can contribute to the regulation of gene expression [15,16]. p300/CBP is ubiquitously expressed and plays an important role in a wide range of biological responses involved in inflammation, cancer and neurodegenerative diseases [26,33,34]. Although CUR-induced p300/CBP inhibition results in a consistent mGlu2 receptor downregulation, the lack of hyperalgesic activity of CUR might be related to the lack of specificity of HAT inhibitors. A number of targets have been shown to be modulated by CUR, many of which might impact pain behavior [27]. Based on our previous works showing that HDAC inhibitor regulate mGlu2 receptor expression via NF-κB activation [5,6], here we focus on the ability of CUR to epigenetically downregulate mGlu2 receptor in DRG and thus to modulate mGlu2/3 analgesic activity. Interestingly, CUR also inhibits NF-κB activation and the expression of its target genes [35]. We have previously shown that systemic administration of CUR is not able to induce histone hypoacetylation in the spinal cord unless CUR is included in a nanocarrier lipid matrix [17]. This is consistent with the low bioavailability of CUR because of its rapid metabolism and pharmacokinetic
characteristics that do not allow the drug to reach high concentration in the CNS [36]. In our study we show that systemically injected CUR is able to induce H3 and H4 hypoacetylation in the DRG. Although CUR is not able to induce hypoacetylation in the spinal cord after systemic injection, the reduced acetylation observed in the DRG might be explained by the lack of the blood brain barrier that increases DRG neuron vulnerability compared to the central nervous system. The effect of CUR in the DRG also explains the downregulation of mGlu2 receptors in the spinal cord. In fact, mGlu2 receptors in the dorsal horn of the spinal cord are presynaptically expressed in the primary sensory afferents whose cell bodies are located in the DRG [28]. The presynaptic localization of mGlu2 receptors on primary afferent neurons, together with the absence of blood brain barrier in DRG also explain the effect of SAHA on mGlu2 receptor expression in the spinal cord despite its poor brain permeability [29]. The lack of analgesic effect in the formalin test by the mGlu2/3 agonist LY379268 in CUR-treated mice is consistent with our previous work showing that LY379268 is not analgesic in mice lacking of the mGlu2 receptors [19,37]. Recently, the role of p300 in chronic pain has been investigated. Zhu and colleagues [38] show that p300 is involved in the development of neuropathic pain and that a reversal of hyperalgesia can be induced by strategies that inhibit or down-regulate p300 in the spinal cord. The authors showed that p300 is up-regulated at day 14 after the induction of neuropathic pain.

Figure 3 CUR and SAHA differently affect the analgesic efficacy of LY379268 in the mouse formalin test. (A, B) CUR-treated mice (100 mg/kg, ip for three consecutive days) did not significantly differ from vehicle-treated mice. The acute administration of LY379268 (3 mg/kg, i.p.) 30 minutes before formalin injection significantly reduced both phases in mice. A single administration of LY379268 (3 mg/kg, i.p.) 30 min before formalin in CUR-pretreated mice failed to induce analgesia in both phases of the formalin test. (C, D) SAHA treated mice (5 mg/kg, sc, for 5 consecutive days) significantly reduced the licking behavior in the second phase of the formalin test. A single administration of LY379268 acutely injected 30 min before formalin was potentiated in SAHA-pretreated mice. Data represent the mean ± S.E.M. of 12 to 16 mice per group. *p<0.05 (Two-way ANOVA + Bonferroni) versus the respective vehicle group, °p<0.05 (Two-way ANOVA + Bonferroni) versus the corresponding group treated with SAHA.
with the chronic constriction injury of the sciatic nerve model. Moreover, the inhibition of p300 HAT by intrathecal administration of a small molecule with p300 HAT inhibitory activity, C646, or by down-regulating p300 with specific small hairpin RNA (shRNA) suppress cyclooxygenase-2 (COX-2) expression [38]. These data are not in contrast with our result showing that the p300/CBP HAT inhibitor, CUR, does not affect pain behavior in the formalin test, since we have shown that, when systemically injected, CUR affects histone acetylation in the DRG, but not in the spinal cord [17]. Consistent with this hypothesis, CUR has been shown to reduce the second phase of the formalin test when intrathecally injected [39].

In this short report we show that a bidirectional modulation of mGlu2 expression in the spinal cord induced by repeated administration of so-called “epigenetic drugs”, such as HDACs or HATs inhibitors, can either potentiate or block the analgesic activity of the mGlu2/3 agonist, LY379268.

Methods

Animals

Adult (8–10 weeks) Wild type CD1 mice were used in this study. All mice were housed under a 12 h light/dark cycle with free access to food and water. All mouse protocols are in accordance with Institutional Animal Care and Use Committee (IACUC) guidelines. All efforts were made to minimize animal suffering and to reduce the number of animals used.

Drugs

Curcumin (Sigma-Aldrich) was dissolved in normal saline solution containing 0.05% dimethyl sulfoxide (DMSO), as previously described [17]. Curcumin was administered to CD1 mice at 100 mg/kg body weight intraperitoneally (i.p.) once a day for three consecutive days with the last injection 24 h before behavioral test. A vehicle solution containing 0.05% DMSO was given as control for the curcumin group. SAHA (Calbiochem) was dissolved in 5% DMSO and injected at 5 mg/kg subcutaneously for 5 consecutive days with the last injection 24 h before behavioral tests. LY379268 (Tocris) was acutely injected at 3 mg/Kg, sc 30 min before the formalin test. A vehicle solution containing 5% DMSO was given as control for the SAHA group.

Behavioral experiments

Formalin test

Formalin (5%, 10 μl; Sigma-Aldrich) was injected subcutaneously into the plantar side of the right hind paw as reported previously [5]. In the formalin test, the total time spent licking or biting the injected hind paw was recorded for each five-minute intervals for one hour post injection. Formalin scores were separated into two phases, phase I (0–10 min) and phase II (15–50 min). A mean response was then calculated for each phase. All tests were performed blind to treatment.

Immunoblotting

Tissues from the lumbar segment of the spinal cord or DRG from L4–L5 were removed and homogenized. Ten micrograms of total protein were separated by 10% SDS polyacrylamide gel electrophoresis and electrophoretically transferred onto protein-sensitive nitrocellulose membranes (Criterion blotter; Bio-Rad Laboratories, Hercules, CA). The membranes were blocked in Odyssey blocker (LI-COR Biosciences, Lincoln, NE) for 1 h, and the following primary antibodies were used: rabbit anti-acetyl H3 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA); rabbit Ac-Histone H4 (Lys 12) (1:200, Santa Cruz Biotechnology, Santa Cruz, CA); rabbit Ac-Histone H3 (Lys 18) (1:200, Abcam); mouse anti actin (1:1000; Sigma Aldrich), Mouse anti-metabotropic Glutamate Receptor 2 (1:500; Abcam). Primary antibodies were incubated overnight at 4°C. The following secondary antibodies were incubated for 1 h at room temperature: goat anti-rabbit antibody labeled with IRD800CW (LICOR) and goat anti-mouse antibody labeled with Alexa Fluor 680 (Invitrogen, Carlsbad, CA). Proteins were detected with the Odyssey Infrared Fluorescence Imaging System (LI-COR).

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

SC, MAS, RWG designed experiments, MZ, CP, SC designed and performed experiments. SC, MZ, CP, MAS and RWG wrote manuscript. All authors read and approved final manuscript.

Acknowledgments

The work is supported by funds from the University of Catania (PRA 2008) to SC, and in part by funds from the NIH (NINDS R01NS42595) to RWG.

Author details

1 Department of Drug Sciences, Section of Pharmacology and Toxicology, University of Catania, 95125 Catania, Italy. 2 Department of Biomedical and Biotechnological Sciences Section of Pharmacology, University of Catania, 95125 Catania, Italy. 3 Washington University Pain Center and Department of Anesthesiology Washington University School of Medicine, St. Louis, MO, USA.

Received: 6 August 2014 Accepted: 4 November 2014 Published: 18 November 2014

References

1. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 1997, 389:349–352.
2. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 2000, 403:41–45.
3. Spange S, Wagner T, Heinzel T, Kra’mer OH: Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2008, 40:185–198.
4. Chiechio S, Copani A, Nicoletti F, Gereau RW 4th: L-acetylcarbimine: a proposed therapeutic agent for painful peripheral neuropathies. Curr Neuropharmacol 2006, 4(3):233–237.
5. Chiechio S, Zammataro M, Morales ME, Busceti CL, Drago F, Gereau RW 4th, Copani A, Nicoletti F: Epigenetic modulation of mGlu2 receptors by
histone deacetylase inhibitors in the treatment of inflammatory pain. *Mol Pharmacol* 2009, 75(5):1014–1020.

6. Chiechio S, Copani A, Zammataro M, Battaglia G, Gereau RW 4th, Nicoletti F: Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. *Trends Pharmacol Sci* 2010, 31(1):153–160.

7. Bai G, Wei D, Zou S, Ren X, Dubner R: Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. *Mol Pain* 2010, 6:51.

8. Chiechio S, Copani A, Gereau RW 4th, Nicoletti F: Acetyl-L-carnitine in neuropathic pain: experimental data. *CNS Drugs* 2007, 21(1):31–38.

9. Chiechio S, Caraciolo A, Baletta E, Storto M, Catania MV, Copani A, Vertecci N, Nicolai R, Calvani M, Melchiori D, Nicoletti F: L-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. *Mol Pharmacol* 2002, 61(5):989–996.

10. Chiechio S, Copani A, De Petris L, Morales ME, Nicoletti F, Gereau RW 4th: Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-κappaB pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of L-acetylcarnitine. *Mol Pain* 2006, 2:20.

11. Zhang Z, Cai YQ, Zou F, Bie B, Pan ZZ: Epigenetic suppression of GAD65 expression mediates persistent pain. *Nat Med* 2011, 17(11):1448–1455.

12. Denk F, Huang W, Sidders B, Bithell A, Crow M, Grist J, Sharma S, Ziemek D, Rice AS, Buckley NJ, McMahon SB: HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain. *Pain* 2013, 154(9):1668–1679.

13. Kukkar A, Singh N, Jaggi AS: Attenuation of neuropathic pain by sodium butyrate in an experimental model of chronic constriction injury in rats. *J Formos Med Assoc* 2013, 112(3):1008.

14. Matushita Y, Araki K, Omitani O, Tukia M, Ueda H: HDAC inhibitors restore C-fibre sensitivity in experimental neuropathic pain model. *Br J Pharmacol* 2013, 170(5):991–998.

15. Balakrubanmayam K, Varier RA, Afat M, Swaminathan V, Siddappa NR, Ranga U, Kundu TK: Curcumin, a novel p300/CBP-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. *J Biol Chem* 2004, 279(51):15653–15671.

16. Kultau SB, Doroshazi J, Roemer NE, Trienzenberg SJ: Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. *Virolology* 2008, 373:239–249.

17. Puglia C, Frasca G, Musumeci T, Rizza L, Puglisi G, Bonina F, Chiechio S: Molecular Pain http://www.molecularpain.com/content/10/1/68

18. Zammataro M, Chiechio S, Montana MC, Traficante A, Copani A, Nicoletti F, Gereau RW 4th: mGlu2 metabotropic glutamate receptors restrain inflammatory pain and mediate the analgesic activity of dual mGlu2/ mGlu3 receptor agonists. *Mol Pain* 2011, 7:65.

19. Neugebauer V, Chen PS, Willis WD: Groups II and III metabotropic glutamate receptors differentially modulate brief and prolonged nociception in primate STT cells. *J Neurophysiol* 2000, 84(6):2998–3009.

20. Chiechio S, Nicoletti F: Metabotropic glutamate receptors and the control of chronic pain. *Curr Opin Pharmacol* 2012, 12(1):26–34.

21. Zammataro M, Hargett GL: Generalization of metabotropic glutamate receptors 2/3 on primary afferent axons in the rat. *Neuroscience* 2001, 105:957–969.

22. Yang D, Gereau RW 4th: Peripheral group II metabotropic glutamate receptors (mGluR2/3) regulate prostaglandin E2-mediated sensitization of capsaicin responses and thermal nociception. *J Neurosci* 2002, 22(1):419–427.

23. Yang D, Gereau RW 4th: Peripheral group II metabotropic glutamate receptors mediate endogenous anti-allodynia in inflammation. *Pain* 2003, 106:411–417.

24. Jones CK, Eberle EL, Peters SC, Monn JA, Shannon HE: Analgesic effects of the selective group II (mGluR2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing. *Neuropharmacology* 2005, 1:206–218.

25. Janknecht R: The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. *Histo Histopathol* 2002, 17:567–668.

26. Zhou H, Beever CS, Huang S: The targets of curcumin. *Curr Drug Targets* 2011, 12:332–347.

27. Carlton SM, Hargett GL: Re-localization of metabotropic glutamate receptors 2/3 on primary afferent axons in the rat. *Neuroscience* 2001, 105:957–969.

28. Hanse J, La H, Plise E, Chen YH, Ding X, Hanania T, Sabaath EV, Alexandrov V, Brunner D, Leahy E, Steiner P, Liu L, Soarce-Levie K, Zhou Q, SAHA enhance synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. *PLoS One* 2013, 8(7):e69964.

29. Kurth M, Holloway T, Garcia-Bea A, Kozielak A, Friedman AK, Moreno JL, Heshmati M, Golden SA, Kennedy PJ, Takahashi N, Dietz DM, Mocci G, Gablondo AM, Hanks J, Umaili A, Callado LF, Galilano AS, Neve RL, Shen L, Buxbaum JD, Han MH, Nediter EJ, Meana JJ, Russo SJ, Gonzalez-Vaeso J: HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. *Nat Neurosci* 2012, 15(1):1254–1259.

30. Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisiano F, Battaglia G, Mathé AA, Pittaluga A, Lionetto L, Simmaco M, Nicoletto F: L-Acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. *Proc Natl Acad Sci U S A* 2013, 110(12):4804–4809.

31. Cuccuzzolli B, Bortolotto V, Valente MM, Ubezio F, Kovocchev A, Canonicak PL, Grilli M: Upregulation of mGlu2 receptors via NF-kB p65 acetylation is involved in the Proneurogenic and antidepressant effects of acetyl-L-carnitine. *Neuropharmacology* 2013, 81(11):2230–2239.

32. Bokhiny A, Peters DJ, Breuning MH: Conjunction dysfunction: CBP/p300 in human disease. *Trends Genet* 1998, 14:178–183.

33. Goodman RH, Smoki S, CBP/p300 in cell growth, transformation, and development. *Genes Dev* 2000, 14:1533–1577.

34. Sen GS, Mohanty S, Hossain DM, Bhattacharyya S, Banerjee S, Chakraborty J, Saha S, Ray P, Bhattacharjee P, Mandal D, Bhattacharya A, Chaptatphyad S, Das T, Sa G: Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB/p300 cross-talk in favor of p53/p300 in breast cancer. *J Biol Chem* 2011, 286(49):42223–42232.

35. Pan MH, Huang TM, Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. *Drug Metab Dispos* 1999, 27:486–494.

36. Chiechio S, Nicoletti F: Metabotropic glutamate receptors and the control of chronic pain. *Curr Opin Pharmacol* 2012, 12(1):26–34.

37. Han YK, Lee SH, Jeong HJ, Kim MS, Yoon MH, Kim WM: Analytic effects of intrathecal curcumin in the rat formalin test. *Korean J Pain* 2012, 25(1):1–6.